H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on MaaT Pharma (MAAT – Research Report) today and set a price target of €21.00.
Vernon Bernardino has given his Buy rating due to a combination of factors related to MaaT Pharma’s promising developments in their clinical trials. The interim safety review of the PHOEBUS trial, which involves MaaT033, showed no excessive mortality, suggesting that the treatment could improve outcomes for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This positive indication supports the potential of MaaT033 to enhance patient survival and reduce significant non-relapse mortality risks, such as acute graft-versus-host disease and infections.
Additionally, the valuation of MaaT Pharma’s stock is supported by a 15% weighted-average cost of capital and a 45% probability of success for their clinical programs, which underpin the projected free cash flows from their therapies. Despite risks such as potential clinical trial failures and regulatory hurdles, the promising early results and strategic financial projections justify the Buy rating and a price target of €21.
In another report released on April 8, Kepler Capital also maintained a Buy rating on the stock with a €15.50 price target.